Attached files
file | filename |
---|---|
EX-99.15 - EXHIBIT 99.15 - JOHNSON & JOHNSON | a8k2018q2exhibit9915.htm |
8-K - 8-K - JOHNSON & JOHNSON | a8-k2018q2.htm |
Exhibit 99.2O
Johnson & Johnson and Subsidiaries | |||||||||
Condensed Consolidated Statement of Earnings | |||||||||
(Unaudited; in Millions Except Per Share Figures) | SECOND QUARTER | ||||||||
2018 | 2017* | Percent | |||||||
Percent | Percent | Increase | |||||||
Amount | to Sales | Amount | to Sales | (Decrease) | |||||
Sales to customers | $ 20,830 | 100.0 | $ 18,839 | 100.0 | 10.6 | ||||
Cost of products sold | 6,927 | 33.3 | 5,846 | 31.0 | 18.5 | ||||
Gross Profit | 13,903 | 66.7 | 12,993 | 69.0 | 7.0 | ||||
Selling, marketing and administrative expenses | 5,743 | 27.5 | 5,289 | 28.1 | 8.6 | ||||
Research and development expense | 2,639 | 12.7 | 2,296 | 12.2 | 14.9 | ||||
Interest (income) expense, net | 127 | 0.6 | 122 | 0.6 | |||||
Other (income) expense, net | 364 | 1.7 | 527 | 2.8 | |||||
Restructuring | 57 | 0.3 | 11 | 0.1 | |||||
Earnings before provision for taxes on income | 4,973 | 23.9 | 4,748 | 25.2 | 4.7 | ||||
Provision for taxes on income | 1,019 | 4.9 | 921 | 4.9 | 10.6 | ||||
Net earnings | $ 3,954 | 19.0 | $ 3,827 | 20.3 | 3.3 | ||||
Net earnings per share (Diluted) | $ 1.45 | $ 1.40 | 3.6 | ||||||
Average shares outstanding (Diluted) | 2,721.3 | 2,741.5 | |||||||
Effective tax rate | 20.5 | % | 19.4 | % | |||||
Adjusted earnings before provision for taxes and net earnings (1) (A) | |||||||||
Earnings before provision for taxes on income | $ 7,014 | 33.7 | $ 6,285 | 33.4 | 11.6 | ||||
Net earnings | $ 5,718 | 27.5 | $ 5,017 | 26.6 | 14.0 | ||||
Net earnings per share (Diluted) | $ 2.10 | $ 1.83 | 14.8 | ||||||
Effective tax rate | 18.5 | % | 20.2 | % | |||||
(1) See Reconciliation of Non-GAAP Financial Measures. | |||||||||
*2017 Statement of Earnings line items have been restated to reflect impact of ASU 2017-07 | |||||||||
(A) NON-GAAP FINANCIAL MEASURES "Adjusted earnings before provision for taxes on income," "adjusted net earnings," "adjusted net earnings per share (diluted)," and "adjusted effective tax rate" are non-GAAP financial measures and should not be considered replacements for GAAP results. The Company provides earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate on an adjusted basis because management believes that these measures provide useful information to investors. Among other things, these measures may assist investors in evaluating the Company's results of operations period over period. In various periods, these measures may exclude such items as intangible asset amortization expense, significant costs associated with acquisitions, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters). Special items may be highly variable, difficult to predict, and of a size that sometimes has substantial impact on the Company's reported results of operations for a period. Management uses these measures internally for planning, forecasting and evaluating the performances of the Company's businesses, including allocating resources and evaluating results relative to employee performance compensation targets. Unlike earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate prepared in accordance with GAAP, adjusted earnings before provision for taxes on income, adjusted net earnings, adjusted net earnings per share (diluted), and adjusted effective tax rate may not be comparable with the calculation of similar measures for other companies. The limitations of using these non-GAAP financial measures as performance measures are that they provide a view of the Company's results of operations without including all events during a period, such as intangible asset amortization expense, the effects of an acquisition, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters) and do not provide a comparable view of the Company's performance to other companies in the health care industry. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP. |
Johnson & Johnson and Subsidiaries | ||||||||||
Condensed Consolidated Statement of Earnings | ||||||||||
(Unaudited; in Millions Except Per Share Figures) | SIX MONTHS | |||||||||
2018 | 2017* | Percent | ||||||||
Percent | Percent | Increase | ||||||||
Amount | to Sales | Amount | to Sales | (Decrease) | ||||||
Sales to customers | $ 40,839 | 100.0 | $ 36,605 | 100.0 | 11.6 | |||||
Cost of products sold | 13,541 | 33.2 | 11,255 | 30.8 | 20.3 | |||||
Gross Profit | 27,298 | 66.8 | 25,350 | 69.2 | 7.7 | |||||
Selling, marketing and administrative expenses | 11,006 | 27.0 | 10,052 | 27.5 | 9.5 | |||||
Research and development expense | 5,043 | 12.3 | 4,366 | 11.9 | 15.5 | |||||
Interest (income) expense, net | 272 | 0.7 | 205 | 0.6 | ||||||
Other (income) expense, net | 424 | 1.0 | 308 | 0.8 | ||||||
Restructuring | 99 | 0.2 | 96 | 0.2 | ||||||
Earnings before provision for taxes on income | 10,454 | 25.6 | 10,323 | 28.2 | 1.3 | |||||
Provision for taxes on income | 2,133 | 5.2 | 2,074 | 5.7 | 2.8 | |||||
Net earnings | $ 8,321 | 20.4 | $ 8,249 | 22.5 | 0.9 | |||||
Net earnings per share (Diluted) | $ 3.05 | $ 3.00 | 1.7 | |||||||
Average shares outstanding (Diluted) | 2,728.5 | 2,749.4 | ||||||||
Effective tax rate | 20.4 | % | 20.1 | % | ||||||
Adjusted earnings before provision for taxes and net earnings (1) (A) | ||||||||||
Earnings before provision for taxes on income | $ 13,872 | 34.0 | $ 12,388 | 33.8 | 12.0 | |||||
Net earnings | $ 11,353 | 27.8 | $ 10,055 | 27.5 | 12.9 | |||||
Net earnings per share (Diluted) | $ 4.16 | $ 3.66 | 13.7 | |||||||
Effective tax rate | 18.2 | % | 18.8 | % | ||||||
(1) See Reconciliation of Non-GAAP Financial Measures. | ||||||||||
*2017 Statement of Earnings line items have been restated to reflect impact of ASU 2017-07 | ||||||||||
(A) NON-GAAP FINANCIAL MEASURES "Adjusted earnings before provision for taxes on income," "adjusted net earnings," "adjusted net earnings per share (diluted)," and "adjusted effective tax rate" are non-GAAP financial measures and should not be considered replacements for GAAP results. The Company provides earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate on an adjusted basis because management believes that these measures provide useful information to investors. Among other things, these measures may assist investors in evaluating the Company's results of operations period over period. In various periods, these measures may exclude such items as intangible asset amortization expense, significant costs associated with acquisitions, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters). Special items may be highly variable, difficult to predict, and of a size that sometimes has substantial impact on the Company's reported results of operations for a period. Management uses these measures internally for planning, forecasting and evaluating the performances of the Company's businesses, including allocating resources and evaluating results relative to employee performance compensation targets. Unlike earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate prepared in accordance with GAAP, adjusted earnings before provision for taxes on income, adjusted net earnings, adjusted net earnings per share (diluted), and adjusted effective tax rate may not be comparable with the calculation of similar measures for other companies. The limitations of using these non-GAAP financial measures as performance measures are that they provide a view of the Company's results of operations without including all events during a period, such as intangible asset amortization expense, the effects of an acquisition, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters) and do not provide a comparable view of the Company's performance to other companies in the health care industry. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP. |
Johnson & Johnson and Subsidiaries | |||||||||
Supplementary Sales Data | |||||||||
(Unaudited; Dollars in Millions) | SECOND QUARTER | ||||||||
Percent Change | |||||||||
2018 | 2017 | Total | Operations | Currency | |||||
Sales to customers by | |||||||||
segment of business | |||||||||
Consumer | |||||||||
U.S. | $ 1,476 | 1,487 | (0.7) | % | (0.7) | — | |||
International | 2,028 | 1,991 | 1.9 | 0.0 | 1.9 | ||||
3,504 | 3,478 | 0.7 | (0.4) | 1.1 | |||||
Pharmaceutical | |||||||||
U.S. | 5,899 | 5,010 | 17.7 | 17.7 | — | ||||
International | 4,455 | 3,625 | 22.9 | 17.5 | 5.4 | ||||
10,354 | 8,635 | 19.9 | 17.6 | 2.3 | |||||
Medical Devices | |||||||||
U.S. | 3,265 | 3,229 | 1.1 | 1.1 | — | ||||
International | 3,707 | 3,497 | 6.0 | 2.5 | 3.5 | ||||
6,972 | 6,726 | 3.7 | 1.9 | 1.8 | |||||
U.S. | 10,640 | 9,726 | 9.4 | 9.4 | — | ||||
International | 10,190 | 9,113 | 11.8 | 7.9 | 3.9 | ||||
Worldwide | $ 20,830 | 18,839 | 10.6 | % | 8.7 | 1.9 |
Johnson & Johnson and Subsidiaries | |||||||||
Supplementary Sales Data | |||||||||
(Unaudited; Dollars in Millions) | SIX MONTHS | ||||||||
Percent Change | |||||||||
2018 | 2017 | Total | Operations | Currency | |||||
Sales to customers by | |||||||||
segment of business | |||||||||
Consumer | |||||||||
U.S. | $ 2,912 | 2,901 | 0.4 | % | 0.4 | — | |||
International | 3,990 | 3,805 | 4.9 | 0.5 | 4.4 | ||||
6,902 | 6,706 | 2.9 | 0.4 | 2.5 | |||||
Pharmaceutical | |||||||||
U.S. | 11,253 | 9,882 | 13.9 | 13.9 | — | ||||
International | 8,945 | 6,998 | 27.8 | 19.9 | 7.9 | ||||
20,198 | 16,880 | 19.7 | 16.4 | 3.3 | |||||
Medical Devices | |||||||||
U.S. | 6,426 | 6,321 | 1.7 | 1.7 | — | ||||
International | 7,313 | 6,698 | 9.2 | 3.3 | 5.9 | ||||
13,739 | 13,019 | 5.5 | 2.5 | 3.0 | |||||
U.S. | 20,591 | 19,104 | 7.8 | 7.8 | — | ||||
International | 20,248 | 17,501 | 15.7 | 9.3 | 6.4 | ||||
Worldwide | $ 40,839 | 36,605 | 11.6 | % | 8.6 | 3.0 |
Johnson & Johnson and Subsidiaries | |||||||||
Supplementary Sales Data | |||||||||
(Unaudited; Dollars in Millions) | SECOND QUARTER | ||||||||
Percent Change | |||||||||
2018 | 2017 | Total | Operations | Currency | |||||
Sales to customers by | |||||||||
geographic area | |||||||||
U.S. | $ 10,640 | 9,726 | 9.4 | % | 9.4 | — | |||
Europe | 4,810 | 4,232 | 13.7 | 6.5 | 7.2 | ||||
Western Hemisphere excluding U.S. | 1,540 | 1,499 | 2.7 | 6.7 | (4.0) | ||||
Asia-Pacific, Africa | 3,840 | 3,382 | 13.5 | 10.2 | 3.3 | ||||
International | 10,190 | 9,113 | 11.8 | 7.9 | 3.9 | ||||
Worldwide | $ 20,830 | 18,839 | 10.6 | % | 8.7 | 1.9 |
Johnson & Johnson and Subsidiaries | |||||||||
Supplementary Sales Data | |||||||||
(Unaudited; Dollars in Millions) | SIX MONTHS | ||||||||
Percent Change | |||||||||
2018 | 2017 | Total | Operations | Currency | |||||
Sales to customers by | |||||||||
geographic area | |||||||||
U.S. | $ 20,591 | 19,104 | 7.8 | % | 7.8 | — | |||
Europe | 9,607 | 8,090 | 18.8 | 8.2 | 10.6 | ||||
Western Hemisphere excluding U.S. | 3,107 | 2,953 | 5.2 | 6.9 | (1.7) | ||||
Asia-Pacific, Africa | 7,534 | 6,458 | 16.7 | 11.9 | 4.8 | ||||
International | 20,248 | 17,501 | 15.7 | 9.3 | 6.4 | ||||
Worldwide | $ 40,839 | 36,605 | 11.6 | % | 8.6 | 3.0 |
Johnson & Johnson and Subsidiaries | |||||||
Reconciliation of Non-GAAP Financial Measures | |||||||
Second Quarter | % Incr. / | ||||||
(Dollars in Millions Except Per Share Data) | 2018 | 2017 | (Decr.) | ||||
Earnings before provision for taxes on income - as reported | $ 4,973 | 4,748 | 4.7 | % | |||
Intangible asset amortization expense | 1,084 | 480 | |||||
Litigation expense, net | 703 | 493 | |||||
Restructuring/Other (1) | 176 | 128 | |||||
Actelion acquisition related cost | 64 | 213 | |||||
Diabetes asset impairment | 4 | 182 | |||||
AMO acquisition related cost | 25 | 41 | |||||
Unrealized loss/(gain) on securities | (39) | — | |||||
Other | 24 | — | |||||
Earnings before provision for taxes on income - as adjusted | $ 7,014 | 6,285 | 11.6 | % | |||
Net Earnings - as reported | $ 3,954 | 3,827 | 3.3 | % | |||
Intangible asset amortization expense | 967 | 378 | |||||
Litigation expense, net | 609 | 352 | |||||
Restructuring/Other | 152 | 101 | |||||
Actelion acquisition related cost | 64 | 199 | |||||
Diabetes asset impairment | 3 | 125 | |||||
AMO acquisition related cost | 22 | 35 | |||||
Unrealized loss/(gain) on securities | (31) | — | |||||
Impact of tax legislation (2) | (40) | — | |||||
Other | 18 | — | |||||
Net Earnings - as adjusted | $ 5,718 | 5,017 | 14.0 | % | |||
Diluted Net Earnings per share - as reported | $ 1.45 | 1.40 | 3.6 | % | |||
Intangible asset amortization expense | 0.36 | 0.14 | |||||
Litigation expense, net | 0.22 | 0.13 | |||||
Restructuring/Other | 0.06 | 0.03 | |||||
Actelion acquisition related cost | 0.02 | 0.07 | |||||
Diabetes asset impairment | — | 0.05 | |||||
AMO acquisition related cost | 0.01 | 0.01 | |||||
Unrealized loss/(gain) on securities | (0.01) | — | |||||
Impact of tax legislation | (0.02) | — | |||||
Other | 0.01 | — | |||||
Diluted Net Earnings per share - as adjusted | $ 2.10 | 1.83 | 14.8 | % | |||
Operational Diluted Net Earnings per share - as adjusted | |||||||
at 2016 foreign currency exchange rates | 1.86 | ||||||
Impact of currency at 2017 foreign currency exchange rates | (0.06) | (0.03) | |||||
Operational Diluted Net Earnings per share - as adjusted | |||||||
at 2017 foreign currency exchange rates | $ 2.04 | 1.83 | 11.5 | % | |||
(1) Includes $44M recorded in cost of products sold and $75M recorded in other (income) expense for the second quarter 2018. Includes $13M recorded in cost of products sold and $104M recorded in other (income) expense for the second quarter 2017. | |||||||
(2) Includes foreign currency translation |
Johnson & Johnson and Subsidiaries | |||||||
Reconciliation of Non-GAAP Financial Measures | |||||||
Six Months YTD | % Incr. / | ||||||
(Dollars in Millions Except Per Share Data) | 2018 | 2017 | (Decr.) | ||||
Earnings before provision for taxes on income - as reported | $ 10,454 | 10,323 | 1.3 | % | |||
Intangible asset amortization expense | 2,199 | 809 | |||||
Litigation expense, net | 703 | 493 | |||||
Restructuring/Other (1) | 283 | 289 | |||||
Actelion acquisition related cost | 160 | 213 | |||||
Diabetes asset impairment | 4 | 182 | |||||
AMO acquisition related cost | 46 | 79 | |||||
Unrealized loss/(gain) on securities | (12) | — | |||||
Other | 35 | — | |||||
Earnings before provision for taxes on income - as adjusted | $ 13,872 | 12,388 | 12.0 | % | |||
Net Earnings - as reported | $ 8,321 | 8,249 | 0.9 | % | |||
Intangible asset amortization expense | 1,963 | 622 | |||||
Litigation expense, net | 609 | 352 | |||||
Restructuring/Other | 233 | 222 | |||||
Actelion acquisition related cost | 156 | 199 | |||||
Diabetes asset impairment | 3 | 125 | |||||
AMO acquisition related cost | 39 | 286 | |||||
Unrealized loss/(gain) on securities | (10) | — | |||||
Impact of tax legislation (2) | 12 | — | |||||
Other | 27 | — | |||||
Net Earnings - as adjusted | $ 11,353 | 10,055 | 12.9 | % | |||
Diluted Net Earnings per share - as reported | $ 3.05 | 3.00 | 1.7 | % | |||
Intangible asset amortization expense | 0.72 | 0.23 | |||||
Litigation expense, net | 0.22 | 0.13 | |||||
Restructuring/Other | 0.09 | 0.08 | |||||
Actelion acquisition related cost | 0.05 | 0.07 | |||||
Diabetes asset impairment | — | 0.05 | |||||
AMO acquisition related cost | 0.01 | 0.10 | |||||
Unrealized loss/(gain) on securities | — | — | |||||
Impact of tax legislation | 0.01 | — | |||||
Other | 0.01 | — | |||||
Diluted Net Earnings per share - as adjusted | $ 4.16 | 3.66 | 13.7 | % | |||
Operational Diluted Net Earnings per share - as adjusted | |||||||
at 2016 foreign currency exchange rates | 3.72 | ||||||
Impact of currency at 2017 foreign currency exchange rates | (0.19) | (0.06) | |||||
Operational Diluted Net Earnings per share - as adjusted | |||||||
at 2017 foreign currency exchange rates | $ 3.97 | 3.66 | 8.5 | % | |||
(1) Includes $50M recorded in cost of products sold and $134M recorded in other (income) expense for six months 2018 YTD. Includes $17M recorded in cost of products sold and $176M recorded in other (income) expense for six months 2017 YTD. | |||||||
(2) Includes foreign currency translation |
Johnson & Johnson and Subsidiaries | ||||||||
Reconciliation of Non-GAAP Financial Measure | ||||||||
Operational Sales Growth Excluding Acquisitions and Divestitures (A) | ||||||||
SECOND QUARTER 2018 ACTUAL vs. 2017 ACTUAL | ||||||||
Segments | ||||||||
Consumer | Pharmaceutical | Medical Devices | Total | |||||
Operational % (1) | ||||||||
WW As Reported: | (0.4)% | 17.6% | 1.9% | 8.7% | ||||
U.S. | (0.7)% | 17.7% | 1.1% | 9.4% | ||||
International | 0.0% | 17.5% | 2.5% | 7.9% | ||||
Pulmonary Hypertension | ||||||||
Actelion | (6.3) | (3.0) | ||||||
U.S. | (7.4) | (3.8) | ||||||
International | (5.2) | (2.0) | ||||||
Cardiovascular / Metabolism / Other | ||||||||
Actelion | (0.3) | (0.1) | ||||||
U.S. | (0.1) | (0.1) | ||||||
International | (0.4) | (0.2) | ||||||
Spine & Other | ||||||||
Codman Neuroscience | 1.0 | 0.4 | ||||||
U.S. | 0.6 | 0.2 | ||||||
International | 1.5 | 0.6 | ||||||
Wound Care / Other | 1.0 | 0.2 | ||||||
Compeed | 0.0 | 0.0 | ||||||
U.S. | 1.7 | 0.4 | ||||||
International | ||||||||
All Other Acquisitions and Divestitures | 0.3 | 0.0 | 0.1 | |||||
U.S. | 0.0 | 0.0 | 0.0 | |||||
International | 0.4 | 0.1 | 0.1 | |||||
WW Ops excluding Acquisitions and Divestitures | 0.9% | 11.0% | 2.9% | 6.3% | ||||
U.S. | (0.7)% | 10.2% | 1.7% | 5.7% | ||||
International | 2.1% | 11.9% | 4.1% | 6.8% | ||||
(1) Operational growth excludes the effect of translational currency | ||||||||
(A) NON-GAAP FINANCIAL MEASURE “Operational sales growth excluding the net impact of acquisitions and divestitures" is a non-GAAP financial measure. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP. Due to the variable nature of acquisitions and divestitures, and the impact they may have on the analysis of underlying business performance and trends, management believes that providing this measure enhances an investor’s understanding of the Company’s performance and may assist in the evaluation of ongoing business operations period over period. This non-GAAP financial measure is presented to permit investors to more fully understand how management assesses the performance of the Company, including for internal evaluation of the performance of the Company's businesses and planning and forecasting for future periods. The use of this non-GAAP financial measure as a performance measure is limited in that it provides a view of the Company's results of operations without including all events during a period and may not provide a comparable view of the Company's performance to that of other companies in the health care industry. |
Johnson & Johnson and Subsidiaries | ||||||||
Reconciliation of Non-GAAP Financial Measure | ||||||||
Operational Sales Growth Excluding Acquisitions and Divestitures (A) | ||||||||
SIX MONTHS 2018 ACTUAL vs. 2017 ACTUAL | ||||||||
Segments | ||||||||
Consumer | Pharmaceutical | Medical Devices | Total | |||||
Operational % (1) | ||||||||
WW As Reported: | 0.4% | 16.4% | 2.5% | 8.6% | ||||
U.S. | 0.4% | 13.9% | 1.7% | 7.8% | ||||
International | 0.5% | 19.9% | 3.3% | 9.3% | ||||
Pulmonary Hypertension | ||||||||
Actelion | (6.8) | (3.1) | ||||||
U.S. | (7.4) | (3.8) | ||||||
International | (5.9) | (2.4) | ||||||
Cardiovascular / Metabolism / Other | ||||||||
Actelion | (0.3) | (0.2) | ||||||
U.S. | (0.2) | (0.1) | ||||||
International | (0.5) | (0.2) | ||||||
Spine & Other | ||||||||
Codman Neuroscience | 1.0 | 0.3 | ||||||
U.S. | 0.6 | 0.2 | ||||||
International | 1.4 | 0.6 | ||||||
Wound Care / Other | ||||||||
Compeed | 0.9 | 0.2 | ||||||
U.S. | 0.0 | 0.0 | ||||||
International | 1.5 | 0.4 | ||||||
Vision | ||||||||
Vision Surgical & Eye Health Business | (1.5) | (0.5) | ||||||
U.S. | (1.4) | (0.5) | ||||||
International | (1.6) | (0.6) | ||||||
All Other Acquisitions and Divestitures | 0.1 | 0.0 | 0.0 | |||||
U.S. | 0.0 | (0.2) | 0.0 | |||||
International | 0.3 | 0.1 | 0.1 | |||||
WW Ops excluding Acquisitions and Divestitures | 1.4% | 9.3% | 2.0% | 5.3% | ||||
U.S. | 0.4% | 6.3% | 0.7% | 3.6% | ||||
International | 2.3% | 13.5% | 3.2% | 7.2% | ||||
(1) Operational growth excludes the effect of translational currency | ||||||||
(A) NON-GAAP FINANCIAL MEASURE “Operational sales growth excluding the net impact of acquisitions and divestitures" is a non-GAAP financial measure. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP. Due to the variable nature of acquisitions and divestitures, and the impact they may have on the analysis of underlying business performance and trends, management believes that providing this measure enhances an investor’s understanding of the Company’s performance and may assist in the evaluation of ongoing business operations period over period. This non-GAAP financial measure is presented to permit investors to more fully understand how management assesses the performance of the Company, including for internal evaluation of the performance of the Company's businesses and planning and forecasting for future periods. The use of this non-GAAP financial measure as a performance measure is limited in that it provides a view of the Company's results of operations without including all events during a period and may not provide a comparable view of the Company's performance to that of other companies in the health care industry. |
Johnson & Johnson | ||||||||||||||
Segment Sales | ||||||||||||||
(Dollars in Millions) | ||||||||||||||
SECOND QUARTER | ||||||||||||||
% Change | ||||||||||||||
2018 | 2017 | Reported | Operational (1) | Currency | ||||||||||
CONSUMER SEGMENT (2) | ||||||||||||||
BABY CARE | ||||||||||||||
US | $ | 89 | 113 | (21.2 | )% | (21.2 | )% | — | % | |||||
Intl | 367 | 381 | (3.7 | ) | (2.7 | ) | (1.0 | ) | ||||||
WW | 456 | 494 | (7.7 | ) | (6.9 | ) | (0.8 | ) | ||||||
BEAUTY | ||||||||||||||
US | 637 | 649 | (1.8 | ) | (1.8 | ) | — | |||||||
Intl | 472 | 427 | 10.5 | 7.3 | 3.2 | |||||||||
WW | 1,109 | 1,076 | 3.1 | 1.8 | 1.3 | |||||||||
ORAL CARE | ||||||||||||||
US | 157 | 150 | 4.7 | 4.7 | — | |||||||||
Intl | 236 | 244 | (3.3 | ) | (5.5 | ) | 2.2 | |||||||
WW | 393 | 394 | (0.3 | ) | (1.7 | ) | 1.4 | |||||||
OTC | ||||||||||||||
US | 454 | 432 | 5.1 | 5.1 | — | |||||||||
Intl | 612 | 574 | 6.6 | 2.5 | 4.1 | |||||||||
WW | 1,066 | 1,006 | 6.0 | 3.7 | 2.3 | |||||||||
WOMEN'S HEALTH | ||||||||||||||
US | 4 | 3 | 33.3 | 33.3 | — | |||||||||
Intl | 276 | 273 | 1.1 | 1.9 | (0.8 | ) | ||||||||
WW | 280 | 276 | 1.4 | 2.2 | (0.8 | ) | ||||||||
WOUND CARE/OTHER | ||||||||||||||
US | 135 | 140 | (3.6 | ) | (3.6 | ) | — | |||||||
Intl | 65 | 92 | (29.3 | ) | (31.3 | ) | 2.0 | |||||||
WW | 200 | 232 | (13.8 | ) | (14.6 | ) | 0.8 | |||||||
TOTAL CONSUMER | ||||||||||||||
US | 1,476 | 1,487 | (0.7 | ) | (0.7 | ) | — | |||||||
Intl | 2,028 | 1,991 | 1.9 | 0.0 | 1.9 | |||||||||
WW | $ | 3,504 | 3,478 | 0.7 | % | (0.4 | )% | 1.1 | % | |||||
See footnotes at end of schedule |
Johnson & Johnson | ||||||||||||||
Segment Sales | ||||||||||||||
(Dollars in Millions) | ||||||||||||||
SECOND QUARTER | ||||||||||||||
% Change | ||||||||||||||
2018 | 2017 | Reported | Operational (1) | Currency | ||||||||||
PHARMACEUTICAL SEGMENT (2) (5) | ||||||||||||||
IMMUNOLOGY | ||||||||||||||
US | $ | 2,317 | 2,101 | 10.3 | % | 10.3 | % | — | % | |||||
Intl | 1,021 | 858 | 19.0 | 14.6 | 4.4 | |||||||||
WW | 3,338 | 2,959 | 12.8 | 11.5 | 1.3 | |||||||||
REMICADE | ||||||||||||||
US | 918 | 1,064 | (13.7 | ) | (13.7 | ) | — | |||||||
US Exports (3) | 104 | 127 | (18.1 | ) | (18.1 | ) | — | |||||||
Intl | 298 | 339 | (12.1 | ) | (14.0 | ) | 1.9 | |||||||
WW | 1,320 | 1,530 | (13.7 | ) | (14.1 | ) | 0.4 | |||||||
SIMPONI / SIMPONI ARIA | ||||||||||||||
US | 274 | 230 | 19.1 | 19.1 | — | |||||||||
Intl | 274 | 209 | 31.1 | 26.9 | 4.2 | |||||||||
WW | 548 | 439 | 24.8 | 22.8 | 2.0 | |||||||||
STELARA | ||||||||||||||
US | 919 | 680 | 35.1 | 35.1 | — | |||||||||
Intl | 422 | 303 | 39.3 | 32.0 | 7.3 | |||||||||
WW | 1,341 | 983 | 36.4 | 34.2 | 2.2 | |||||||||
OTHER IMMUNOLOGY | ||||||||||||||
US | 102 | — | * | * | — | |||||||||
Intl | 27 | 7 | * | * | * | |||||||||
WW | 129 | 7 | * | * | * | |||||||||
INFECTIOUS DISEASES | ||||||||||||||
US | 328 | 341 | (3.8 | ) | (3.8 | ) | — | |||||||
Intl | 521 | 451 | 15.5 | 11.0 | 4.5 | |||||||||
WW | 849 | 792 | 7.2 | 4.6 | 2.6 | |||||||||
EDURANT / rilpivirine | ||||||||||||||
US | 15 | 17 | (11.8 | ) | (11.8 | ) | — | |||||||
Intl | 196 | 162 | 21.0 | 13.1 | 7.9 | |||||||||
WW | 211 | 179 | 17.9 | 10.7 | 7.2 | |||||||||
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA | ||||||||||||||
US | 277 | 278 | (0.4 | ) | (0.4 | ) | — | |||||||
Intl | 215 | 176 | 22.2 | 18.8 | 3.4 | |||||||||
WW | 492 | 454 | 8.4 | 7.1 | 1.3 | |||||||||
OTHER INFECTIOUS DISEASES | ||||||||||||||
US | 36 | 46 | (21.7 | ) | (21.7 | ) | — | |||||||
Intl | 110 | 113 | (2.7 | ) | (4.1 | ) | 1.4 | |||||||
WW | 146 | 159 | (8.2 | ) | (9.2 | ) | 1.0 | |||||||
See footnotes at end of schedule |
Johnson & Johnson | ||||||||||||||
Segment Sales | ||||||||||||||
(Dollars in Millions) | ||||||||||||||
SECOND QUARTER | ||||||||||||||
% Change | ||||||||||||||
2018 | 2017 | Reported | Operational (1) | Currency | ||||||||||
PHARMACEUTICAL SEGMENT (2) (5) (Continued) | ||||||||||||||
NEUROSCIENCE | ||||||||||||||
US | $ | 639 | 620 | 3.1 | % | 3.1 | % | — | % | |||||
Intl | 889 | 847 | 5.0 | 1.4 | 3.6 | |||||||||
WW | 1,528 | 1,467 | 4.2 | 2.1 | 2.1 | |||||||||
CONCERTA / methylphenidate | ||||||||||||||
US | 68 | 76 | (10.5 | ) | (10.5 | ) | — | |||||||
Intl | 115 | 105 | 9.5 | 6.9 | 2.6 | |||||||||
WW | 183 | 181 | 1.1 | (0.4 | ) | 1.5 | ||||||||
INVEGA SUSTENNA / XEPLION / TRINZA / TREVICTA | ||||||||||||||
US | 438 | 387 | 13.2 | 13.2 | — | |||||||||
Intl | 282 | 242 | 16.5 | 10.5 | 6.0 | |||||||||
WW | 720 | 629 | 14.5 | 12.2 | 2.3 | |||||||||
RISPERDAL CONSTA | ||||||||||||||
US | 80 | 91 | (12.1 | ) | (12.1 | ) | — | |||||||
Intl | 108 | 116 | (6.9 | ) | (10.3 | ) | 3.4 | |||||||
WW | 188 | 207 | (9.2 | ) | (11.1 | ) | 1.9 | |||||||
OTHER NEUROSCIENCE | ||||||||||||||
US | 53 | 66 | (19.7 | ) | (19.7 | ) | — | |||||||
Intl | 384 | 384 | 0.0 | (2.4 | ) | 2.4 | ||||||||
WW | 437 | 450 | (2.9 | ) | (5.0 | ) | 2.1 | |||||||
ONCOLOGY | ||||||||||||||
US | 1,085 | 697 | 55.7 | 55.7 | — | |||||||||
Intl | 1,371 | 1,030 | 33.1 | 27.2 | 5.9 | |||||||||
WW | 2,456 | 1,727 | 42.2 | 38.7 | 3.5 | |||||||||
DARZALEX | ||||||||||||||
US | 298 | 212 | 40.6 | 40.6 | — | |||||||||
Intl | 213 | 87 | * | * | * | |||||||||
WW | 511 | 299 | 70.9 | 67.7 | 3.2 | |||||||||
IMBRUVICA | ||||||||||||||
US | 250 | 202 | 23.8 | 23.8 | — | |||||||||
Intl | 370 | 248 | 49.2 | 42.7 | 6.5 | |||||||||
WW | 620 | 450 | 37.8 | 34.2 | 3.6 | |||||||||
VELCADE | ||||||||||||||
US | — | — | — | — | — | |||||||||
Intl | 280 | 290 | (3.4 | ) | (8.0 | ) | 4.6 | |||||||
WW | 280 | 290 | (3.4 | ) | (8.0 | ) | 4.6 | |||||||
ZYTIGA | ||||||||||||||
US | 486 | 241 | * | * | — | |||||||||
Intl | 423 | 317 | 33.4 | 27.3 | 6.1 | |||||||||
WW | 909 | 558 | 62.9 | 59.5 | 3.4 | |||||||||
OTHER ONCOLOGY | ||||||||||||||
US | 51 | 42 | 21.4 | 21.4 | — | |||||||||
Intl | 85 | 88 | (3.4 | ) | (6.8 | ) | 3.4 | |||||||
WW | 136 | 130 | 4.6 | 2.3 | 2.3 | |||||||||
See footnotes at end of schedule |
Johnson & Johnson | ||||||||||||
Segment Sales | ||||||||||||
(Dollars in Millions) | ||||||||||||
SECOND QUARTER | ||||||||||||
% Change | ||||||||||||
2018 | 2017 | Reported | Operational (1) | Currency | ||||||||
PHARMACEUTICAL SEGMENT (2) (5) (Continued) | ||||||||||||
PULMONARY HYPERTENSION (4) | ||||||||||||
US | $ | 429 | 37 | * | * | — | % | |||||
Intl | 236 | 48 | * | * | * | |||||||
WW | 665 | 85 | * | * | * | |||||||
OPSUMIT | ||||||||||||
US | 180 | 24 | * | * | — | |||||||
Intl | 131 | 21 | * | * | * | |||||||
WW | 311 | 45 | * | * | * | |||||||
TRACLEER | ||||||||||||
US | 71 | 2 | * | * | — | |||||||
Intl | 72 | 24 | * | * | * | |||||||
WW | 143 | 26 | * | * | * | |||||||
UPTRAVI | ||||||||||||
US | 155 | 8 | * | * | — | |||||||
Intl | 16 | 1 | * | * | * | |||||||
WW | 171 | 9 | * | * | * | |||||||
OTHER | ||||||||||||
US | 23 | 3 | * | * | — | |||||||
Intl | 17 | 2 | * | * | * | |||||||
WW | 40 | 5 | * | * | * | |||||||
See footnotes at end of schedule |
Johnson & Johnson | ||||||||||||||
Segment Sales | ||||||||||||||
(Dollars in Millions) | ||||||||||||||
SECOND QUARTER | ||||||||||||||
% Change | ||||||||||||||
2018 | 2017 | Reported | Operational (1) | Currency | ||||||||||
PHARMACEUTICAL SEGMENT (2) (5) (Continued) | ||||||||||||||
CARDIOVASCULAR / METABOLISM / OTHER | ||||||||||||||
US | $ | 1,101 | 1,214 | (9.3 | )% | (9.3 | )% | — | % | |||||
Intl | 417 | 391 | 6.6 | 1.9 | 4.7 | |||||||||
WW | 1,518 | 1,605 | (5.4 | ) | (6.6 | ) | 1.2 | |||||||
XARELTO | ||||||||||||||
US | 679 | 642 | 5.8 | 5.8 | — | |||||||||
Intl | — | — | — | — | — | |||||||||
WW | 679 | 642 | 5.8 | 5.8 | — | |||||||||
INVOKANA / INVOKAMET | ||||||||||||||
US | 169 | 256 | (34.0 | ) | (34.0 | ) | — | |||||||
Intl | 46 | 39 | 17.9 | 13.0 | 4.9 | |||||||||
WW | 215 | 295 | (27.1 | ) | (27.7 | ) | 0.6 | |||||||
PROCRIT / EPREX | ||||||||||||||
US | 156 | 174 | (10.3 | ) | (10.3 | ) | — | |||||||
Intl | 80 | 81 | (1.2 | ) | (5.9 | ) | 4.7 | |||||||
WW | 236 | 255 | (7.5 | ) | (9.0 | ) | 1.5 | |||||||
OTHER | ||||||||||||||
US | 97 | 142 | (31.7 | ) | (31.7 | ) | — | |||||||
Intl | 291 | 271 | 7.4 | 2.7 | 4.7 | |||||||||
WW | 388 | 413 | (6.1 | ) | (9.2 | ) | 3.1 | |||||||
TOTAL PHARMACEUTICAL | ||||||||||||||
US | 5,899 | 5,010 | 17.7 | 17.7 | — | |||||||||
Intl | 4,455 | 3,625 | 22.9 | 17.5 | 5.4 | |||||||||
WW | $ | 10,354 | 8,635 | 19.9 | % | 17.6 | % | 2.3 | % | |||||
See footnotes at end of schedule |
Johnson & Johnson | ||||||||||||||
Segment Sales | ||||||||||||||
(Dollars in Millions) | ||||||||||||||
SECOND QUARTER | ||||||||||||||
% Change | ||||||||||||||
2018 | 2017 | Reported | Operational (1) | Currency | ||||||||||
MEDICAL DEVICES SEGMENT (2) (5) | ||||||||||||||
DIABETES CARE | ||||||||||||||
US | $ | 129 | 160 | (19.4 | )% | (19.4 | )% | — | % | |||||
Intl | 226 | 261 | (13.4 | ) | (16.3 | ) | 2.9 | |||||||
WW | 355 | 421 | (15.7 | ) | (17.5 | ) | 1.8 | |||||||
INTERVENTIONAL SOLUTIONS | ||||||||||||||
US | 323 | 285 | 13.3 | 13.3 | — | |||||||||
Intl | 344 | 288 | 19.4 | 14.1 | 5.3 | |||||||||
WW | 667 | 573 | 16.4 | 13.7 | 2.7 | |||||||||
ORTHOPAEDICS | ||||||||||||||
US | 1,332 | 1,367 | (2.6 | ) | (2.6 | ) | — | |||||||
Intl | 930 | 926 | 0.4 | (3.6 | ) | 4.0 | ||||||||
WW | 2,262 | 2,293 | (1.4 | ) | (3.0 | ) | 1.6 | |||||||
HIPS | ||||||||||||||
US | 211 | 208 | 1.4 | 1.4 | — | |||||||||
Intl | 149 | 142 | 4.9 | 0.8 | 4.1 | |||||||||
WW | 360 | 350 | 2.9 | 1.2 | 1.7 | |||||||||
KNEES | ||||||||||||||
US | 229 | 236 | (3.0 | ) | (3.0 | ) | — | |||||||
Intl | 153 | 149 | 2.7 | (0.8 | ) | 3.5 | ||||||||
WW | 382 | 385 | (0.8 | ) | (2.2 | ) | 1.4 | |||||||
TRAUMA | ||||||||||||||
US | 394 | 390 | 1.0 | 1.0 | — | |||||||||
Intl | 281 | 253 | 11.1 | 6.7 | 4.4 | |||||||||
WW | 675 | 643 | 5.0 | 3.3 | 1.7 | |||||||||
SPINE & OTHER | ||||||||||||||
US | 498 | 533 | (6.6 | ) | (6.6 | ) | — | |||||||
Intl | 347 | 382 | (9.2 | ) | (13.2 | ) | 4.0 | |||||||
WW | 845 | 915 | (7.7 | ) | (9.4 | ) | 1.7 | |||||||
See footnotes at end of schedule |
Johnson & Johnson | ||||||||||||||
Segment Sales | ||||||||||||||
(Dollars in Millions) | ||||||||||||||
SECOND QUARTER | ||||||||||||||
% Change | ||||||||||||||
2018 | 2017 | Reported | Operational (1) | Currency | ||||||||||
MEDICAL DEVICES SEGMENT (2) (5) (Continued) | ||||||||||||||
SURGERY | ||||||||||||||
US | $ | 1,022 | 1,012 | 1.0 | % | 1.0 | % | — | % | |||||
Intl | 1,493 | 1,372 | 8.8 | 5.4 | 3.4 | |||||||||
WW | 2,515 | 2,384 | 5.5 | 3.5 | 2.0 | |||||||||
ADVANCED | ||||||||||||||
US | 402 | 400 | 0.5 | 0.5 | — | |||||||||
Intl | 603 | 533 | 13.1 | 9.1 | 4.0 | |||||||||
WW | 1,005 | 933 | 7.7 | 5.4 | 2.3 | |||||||||
GENERAL | ||||||||||||||
US | 436 | 423 | 3.1 | 3.1 | — | |||||||||
Intl | 733 | 691 | 6.1 | 2.9 | 3.2 | |||||||||
WW | 1,169 | 1,114 | 4.9 | 2.9 | 2.0 | |||||||||
SPECIALTY | ||||||||||||||
US | 184 | 189 | (2.6 | ) | (2.6 | ) | — | |||||||
Intl | 157 | 148 | 6.1 | 4.2 | 1.9 | |||||||||
WW | 341 | 337 | 1.2 | 0.4 | 0.8 | |||||||||
VISION | ||||||||||||||
US | 459 | 405 | 13.3 | 13.3 | — | |||||||||
Intl | 714 | 650 | 9.8 | 7.2 | 2.6 | |||||||||
WW | 1,173 | 1,055 | 11.2 | 9.6 | 1.6 | |||||||||
CONTACT LENSES / OTHER | ||||||||||||||
US | 320 | 274 | 16.8 | 16.8 | — | |||||||||
Intl | 524 | 479 | 9.4 | 6.8 | 2.6 | |||||||||
WW | 844 | 753 | 12.1 | 10.4 | 1.7 | |||||||||
SURGICAL | ||||||||||||||
US | 139 | 131 | 6.1 | 6.1 | — | |||||||||
Intl | 190 | 171 | 11.1 | 8.6 | 2.5 | |||||||||
WW | 329 | 302 | 8.9 | 7.5 | 1.4 | |||||||||
TOTAL MEDICAL DEVICES | ||||||||||||||
US | 3,265 | 3,229 | 1.1 | 1.1 | — | |||||||||
Intl | 3,707 | 3,497 | 6.0 | 2.5 | 3.5 | |||||||||
WW | $ | 6,972 | 6,726 | 3.7 | % | 1.9 | % | 1.8 | % | |||||
See footnotes at end of schedule |
Johnson & Johnson | ||||||||||||||
Segment Sales | ||||||||||||||
(Dollars in Millions) | ||||||||||||||
SIX MONTHS | ||||||||||||||
% Change | ||||||||||||||
2018 | 2017 | Reported | Operational (1) | Currency | ||||||||||
CONSUMER SEGMENT (2) | ||||||||||||||
BABY CARE | ||||||||||||||
US | $ | 186 | 226 | (17.7 | )% | (17.7 | )% | — | % | |||||
Intl | 727 | 723 | 0.6 | (0.8 | ) | 1.4 | ||||||||
WW | 913 | 949 | (3.8 | ) | (4.8 | ) | 1.0 | |||||||
BEAUTY | ||||||||||||||
US | 1,248 | 1,216 | 2.6 | 2.6 | — | |||||||||
Intl | 945 | 841 | 12.4 | 6.8 | 5.6 | |||||||||
WW | 2,193 | 2,057 | 6.6 | 4.3 | 2.3 | |||||||||
ORAL CARE | ||||||||||||||
US | 314 | 306 | 2.6 | 2.6 | — | |||||||||
Intl | 458 | 450 | 1.8 | (2.7 | ) | 4.5 | ||||||||
WW | 772 | 756 | 2.1 | (0.6 | ) | 2.7 | ||||||||
OTC | ||||||||||||||
US | 919 | 909 | 1.1 | 1.1 | — | |||||||||
Intl | 1,219 | 1,110 | 9.8 | 3.2 | 6.6 | |||||||||
WW | 2,138 | 2,019 | 5.9 | 2.2 | 3.7 | |||||||||
WOMEN'S HEALTH | ||||||||||||||
US | 7 | 6 | 16.7 | 16.7 | — | |||||||||
Intl | 516 | 512 | 0.8 | (1.1 | ) | 1.9 | ||||||||
WW | 523 | 518 | 1.0 | (0.9 | ) | 1.9 | ||||||||
WOUND CARE/OTHER | ||||||||||||||
US | 238 | 238 | 0.0 | 0.0 | — | |||||||||
Intl | 125 | 169 | (26.0 | ) | (29.2 | ) | 3.2 | |||||||
WW | 363 | 407 | (10.8 | ) | (12.1 | ) | 1.3 | |||||||
TOTAL CONSUMER | ||||||||||||||
US | 2,912 | 2,901 | 0.4 | 0.4 | — | |||||||||
Intl | 3,990 | 3,805 | 4.9 | 0.5 | 4.4 | |||||||||
WW | $ | 6,902 | 6,706 | 2.9 | % | 0.4 | % | 2.5 | % | |||||
See footnotes at end of schedule |
Johnson & Johnson | ||||||||||||||
Segment Sales | ||||||||||||||
(Dollars in Millions) | ||||||||||||||
SIX MONTHS | ||||||||||||||
% Change | ||||||||||||||
2018 | 2017 | Reported | Operational (1) | Currency | ||||||||||
PHARMACEUTICAL SEGMENT (2) (5) | ||||||||||||||
IMMUNOLOGY | ||||||||||||||
US | $ | 4,317 | 4,224 | 2.2 | % | 2.2 | % | — | % | |||||
Intl | 2,063 | 1,665 | 23.9 | 17.0 | 6.9 | |||||||||
WW | 6,380 | 5,889 | 8.3 | 6.3 | 2.0 | |||||||||
REMICADE | ||||||||||||||
US | 1,834 | 2,246 | (18.3 | ) | (18.3 | ) | — | |||||||
US Exports (3) | 246 | 292 | (15.8 | ) | (15.8 | ) | — | |||||||
Intl | 629 | 664 | (5.3 | ) | (9.0 | ) | 3.7 | |||||||
WW | 2,709 | 3,202 | (15.4 | ) | (16.2 | ) | 0.8 | |||||||
SIMPONI / SIMPONI ARIA | ||||||||||||||
US | 498 | 459 | 8.5 | 8.5 | — | |||||||||
Intl | 568 | 408 | 39.2 | 32.0 | 7.2 | |||||||||
WW | 1,066 | 867 | 23.0 | 19.6 | 3.4 | |||||||||
STELARA | ||||||||||||||
US | 1,571 | 1,227 | 28.0 | 28.0 | — | |||||||||
Intl | 831 | 579 | 43.5 | 32.9 | 10.6 | |||||||||
WW | 2,402 | 1,806 | 33.0 | 29.6 | 3.4 | |||||||||
OTHER IMMUNOLOGY | ||||||||||||||
US | 168 | — | * | * | — | |||||||||
Intl | 35 | 14 | * | * | * | |||||||||
WW | 203 | 14 | * | * | * | |||||||||
INFECTIOUS DISEASES | ||||||||||||||
US | 661 | 667 | (0.9 | ) | (0.9 | ) | — | |||||||
Intl | 1,018 | 874 | 16.5 | 8.5 | 8.0 | |||||||||
WW | 1,679 | 1,541 | 9.0 | 4.5 | 4.5 | |||||||||
EDURANT / rilpivirine | ||||||||||||||
US | 29 | 29 | 0.0 | 0.0 | — | |||||||||
Intl | 392 | 299 | 31.1 | 18.6 | 12.5 | |||||||||
WW | 421 | 328 | 28.4 | 17.0 | 11.4 | |||||||||
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA | ||||||||||||||
US | 550 | 537 | 2.4 | 2.4 | — | |||||||||
Intl | 420 | 347 | 21.0 | 14.1 | 6.9 | |||||||||
WW | 970 | 884 | 9.7 | 7.0 | 2.7 | |||||||||
OTHER INFECTIOUS DISEASES | ||||||||||||||
US | 82 | 101 | (18.8 | ) | (18.8 | ) | — | |||||||
Intl | 206 | 228 | (9.6 | ) | (13.3 | ) | 3.7 | |||||||
WW | 288 | 329 | (12.5 | ) | (15.1 | ) | 2.6 | |||||||
See footnotes at end of schedule |
Johnson & Johnson | ||||||||||||||
Segment Sales | ||||||||||||||
(Dollars in Millions) | ||||||||||||||
SIX MONTHS | ||||||||||||||
% Change | ||||||||||||||
2018 | 2017 | Reported | Operational (1) | Currency | ||||||||||
PHARMACEUTICAL SEGMENT (2) (5) (Continued) | ||||||||||||||
NEUROSCIENCE | ||||||||||||||
US | $ | 1,263 | 1,284 | (1.6 | )% | (1.6 | )% | — | % | |||||
Intl | 1,824 | 1,680 | 8.6 | 2.4 | 6.2 | |||||||||
WW | 3,087 | 2,964 | 4.1 | 0.6 | 3.5 | |||||||||
CONCERTA / methylphenidate | ||||||||||||||
US | 134 | 184 | (27.2 | ) | (27.2 | ) | — | |||||||
Intl | 222 | 206 | 7.8 | 3.1 | 4.7 | |||||||||
WW | 356 | 390 | (8.7 | ) | (11.2 | ) | 2.5 | |||||||
INVEGA SUSTENNA / XEPLION / TRINZA / TREVICTA | ||||||||||||||
US | 838 | 759 | 10.4 | 10.4 | — | |||||||||
Intl | 578 | 474 | 21.9 | 12.8 | 9.1 | |||||||||
WW | 1,416 | 1,233 | 14.8 | 11.3 | 3.5 | |||||||||
RISPERDAL CONSTA | ||||||||||||||
US | 162 | 186 | (12.9 | ) | (12.9 | ) | — | |||||||
Intl | 222 | 228 | (2.6 | ) | (8.7 | ) | 6.1 | |||||||
WW | 384 | 414 | (7.2 | ) | (10.6 | ) | 3.4 | |||||||
OTHER NEUROSCIENCE | ||||||||||||||
US | 129 | 155 | (16.8 | ) | (16.8 | ) | — | |||||||
Intl | 802 | 772 | 3.9 | (1.0 | ) | 4.9 | ||||||||
WW | 931 | 927 | 0.4 | (3.6 | ) | 4.0 | ||||||||
ONCOLOGY | ||||||||||||||
US | 2,018 | 1,361 | 48.3 | 48.3 | — | |||||||||
Intl | 2,749 | 1,960 | 40.3 | 30.7 | 9.6 | |||||||||
WW | 4,767 | 3,321 | 43.5 | 37.8 | 5.7 | |||||||||
DARZALEX | ||||||||||||||
US | 562 | 413 | 36.1 | 36.1 | — | |||||||||
Intl | 381 | 141 | * | * | * | |||||||||
WW | 943 | 554 | 70.2 | 65.8 | 4.4 | |||||||||
IMBRUVICA | ||||||||||||||
US | 477 | 392 | 21.7 | 21.7 | — | |||||||||
Intl | 730 | 467 | 56.3 | 45.7 | 10.6 | |||||||||
WW | 1,207 | 859 | 40.5 | 34.7 | 5.8 | |||||||||
VELCADE | ||||||||||||||
US | — | — | — | — | — | |||||||||
Intl | 593 | 570 | 4.0 | (3.4 | ) | 7.4 | ||||||||
WW | 593 | 570 | 4.0 | (3.4 | ) | 7.4 | ||||||||
ZYTIGA | ||||||||||||||
US | 893 | 474 | 88.4 | 88.4 | — | |||||||||
Intl | 861 | 607 | 41.8 | 31.8 | 10.0 | |||||||||
WW | 1,754 | 1,081 | 62.3 | 56.7 | 5.6 | |||||||||
OTHER ONCOLOGY | ||||||||||||||
US | 86 | 82 | 4.9 | 4.9 | — | |||||||||
Intl | 184 | 175 | 5.1 | (1.5 | ) | 6.6 | ||||||||
WW | 270 | 257 | 5.1 | 0.6 | 4.5 | |||||||||
See footnotes at end of schedule |
Johnson & Johnson | ||||||||||||
Segment Sales | ||||||||||||
(Dollars in Millions) | ||||||||||||
SIX MONTHS | ||||||||||||
% Change | ||||||||||||
2018 | 2017 | Reported | Operational (1) | Currency | ||||||||
PHARMACEUTICAL SEGMENT (2) (5) (Continued) | ||||||||||||
PULMONARY HYPERTENSION (4) | ||||||||||||
US | $ | 790 | 37 | * | * | — | % | |||||
Intl | 460 | 48 | * | * | * | |||||||
WW | 1,250 | 85 | * | * | * | |||||||
OPSUMIT | ||||||||||||
US | 329 | 24 | * | * | — | |||||||
Intl | 253 | 21 | * | * | * | |||||||
WW | 582 | 45 | * | * | * | |||||||
TRACLEER | ||||||||||||
US | 139 | 2 | * | * | — | |||||||
Intl | 144 | 24 | * | * | * | |||||||
WW | 283 | 26 | * | * | * | |||||||
UPTRAVI | ||||||||||||
US | 279 | 8 | * | * | — | |||||||
Intl | 32 | 1 | * | * | * | |||||||
WW | 311 | 9 | * | * | * | |||||||
OTHER | ||||||||||||
US | 43 | 3 | * | * | — | |||||||
Intl | 31 | 2 | * | * | * | |||||||
WW | 74 | 5 | * | * | * | |||||||
See footnotes at end of schedule |
Johnson & Johnson | ||||||||||||||
Segment Sales | ||||||||||||||
(Dollars in Millions) | ||||||||||||||
SIX MONTHS | ||||||||||||||
% Change | ||||||||||||||
2018 | 2017 | Reported | Operational (1) | Currency | ||||||||||
PHARMACEUTICAL SEGMENT (2) (5) (Continued) | ||||||||||||||
CARDIOVASCULAR / METABOLISM / OTHER | ||||||||||||||
US | $ | 2,204 | 2,309 | (4.5 | )% | (4.5 | )% | — | % | |||||
Intl | 831 | 771 | 7.8 | 1.7 | 6.1 | |||||||||
WW | 3,035 | 3,080 | (1.5 | ) | (3.0 | ) | 1.5 | |||||||
XARELTO | ||||||||||||||
US | 1,257 | 1,155 | 8.8 | 8.8 | — | |||||||||
Intl | — | — | — | — | — | |||||||||
WW | 1,257 | 1,155 | 8.8 | 8.8 | — | |||||||||
INVOKANA / INVOKAMET | ||||||||||||||
US | 373 | 503 | (25.8 | ) | (25.8 | ) | — | |||||||
Intl | 90 | 76 | 18.4 | 11.7 | 6.7 | |||||||||
WW | 463 | 579 | (20.0 | ) | (20.9 | ) | 0.9 | |||||||
PROCRIT / EPREX | ||||||||||||||
US | 345 | 343 | 0.6 | 0.6 | — | |||||||||
Intl | 167 | 159 | 5.0 | (1.7 | ) | 6.7 | ||||||||
WW | 512 | 502 | 2.0 | (0.1 | ) | 2.1 | ||||||||
OTHER | ||||||||||||||
US | 229 | 308 | (25.6 | ) | (25.6 | ) | — | |||||||
Intl | 574 | 536 | 7.1 | 1.3 | 5.8 | |||||||||
WW | 803 | 844 | (4.9 | ) | (8.6 | ) | 3.7 | |||||||
TOTAL PHARMACEUTICAL | ||||||||||||||
US | 11,253 | 9,882 | 13.9 | 13.9 | — | |||||||||
Intl | 8,945 | 6,998 | 27.8 | 19.9 | 7.9 | |||||||||
WW | $ | 20,198 | 16,880 | 19.7 | % | 16.4 | % | 3.3 | % | |||||
See footnotes at end of schedule |
Johnson & Johnson | ||||||||||||||
Segment Sales | ||||||||||||||
(Dollars in Millions) | ||||||||||||||
SIX MONTHS | ||||||||||||||
% Change | ||||||||||||||
2018 | 2017 | Reported | Operational (1) | Currency | ||||||||||
MEDICAL DEVICES SEGMENT (2) (5) | ||||||||||||||
DIABETES CARE | ||||||||||||||
US | $ | 246 | 314 | (21.7 | )% | (21.7 | )% | — | % | |||||
Intl | 448 | 506 | (11.5 | ) | (16.6 | ) | 5.1 | |||||||
WW | 694 | 820 | (15.4 | ) | (18.5 | ) | 3.1 | |||||||
DIAGNOSTICS | ||||||||||||||
US | — | — | — | — | — | |||||||||
Intl | — | 1 | * | * | * | |||||||||
WW | — | 1 | * | * | * | |||||||||
INTERVENTIONAL SOLUTIONS | ||||||||||||||
US | 627 | 564 | 11.2 | 11.2 | — | |||||||||
Intl | 680 | 558 | 21.9 | 14.2 | 7.7 | |||||||||
WW | 1,307 | 1,122 | 16.5 | 12.7 | 3.8 | |||||||||
ORTHOPAEDICS | ||||||||||||||
US | 2,639 | 2,726 | (3.2 | ) | (3.2 | ) | — | |||||||
Intl | 1,873 | 1,842 | 1.7 | (4.6 | ) | 6.3 | ||||||||
WW | 4,512 | 4,568 | (1.2 | ) | (3.8 | ) | 2.6 | |||||||
HIPS | ||||||||||||||
US | 420 | 417 | 0.7 | 0.7 | — | |||||||||
Intl | 303 | 285 | 6.3 | (0.2 | ) | 6.5 | ||||||||
WW | 723 | 702 | 3.0 | 0.3 | 2.7 | |||||||||
KNEES | ||||||||||||||
US | 457 | 482 | (5.2 | ) | (5.2 | ) | — | |||||||
Intl | 312 | 301 | 3.7 | (2.5 | ) | 6.2 | ||||||||
WW | 769 | 783 | (1.8 | ) | (4.2 | ) | 2.4 | |||||||
TRAUMA | ||||||||||||||
US | 801 | 781 | 2.6 | 2.6 | — | |||||||||
Intl | 570 | 504 | 13.1 | 6.2 | 6.9 | |||||||||
WW | 1,371 | 1,285 | 6.7 | 4.0 | 2.7 | |||||||||
SPINE & OTHER | ||||||||||||||
US | 961 | 1,046 | (8.1 | ) | (8.1 | ) | — | |||||||
Intl | 688 | 752 | (8.5 | ) | (14.5 | ) | 6.0 | |||||||
WW | 1,649 | 1,798 | (8.3 | ) | (10.8 | ) | 2.5 | |||||||
See footnotes at end of schedule |
Johnson & Johnson | ||||||||||||||
Segment Sales | ||||||||||||||
(Dollars in Millions) | ||||||||||||||
SIX MONTHS | ||||||||||||||
% Change | ||||||||||||||
2018 | 2017 | Reported | Operational (1) | Currency | ||||||||||
MEDICAL DEVICES SEGMENT (2) (5) (Continued) | ||||||||||||||
SURGERY | ||||||||||||||
US | $ | 2,015 | 2,007 | 0.4 | % | 0.4 | % | — | % | |||||
Intl | 2,923 | 2,648 | 10.4 | 4.7 | 5.7 | |||||||||
WW | 4,938 | 4,655 | 6.1 | 2.9 | 3.2 | |||||||||
ADVANCED | ||||||||||||||
US | 795 | 792 | 0.4 | 0.4 | — | |||||||||
Intl | 1,176 | 1,018 | 15.5 | 9.3 | 6.2 | |||||||||
WW | 1,971 | 1,810 | 8.9 | 5.4 | 3.5 | |||||||||
GENERAL | ||||||||||||||
US | 859 | 846 | 1.5 | 1.5 | — | |||||||||
Intl | 1,437 | 1,342 | 7.1 | 1.5 | 5.6 | |||||||||
WW | 2,296 | 2,188 | 4.9 | 1.5 | 3.4 | |||||||||
SPECIALTY | ||||||||||||||
US | 361 | 369 | (2.2 | ) | (2.2 | ) | — | |||||||
Intl | 310 | 288 | 7.6 | 3.4 | 4.2 | |||||||||
WW | 671 | 657 | 2.1 | 0.3 | 1.8 | |||||||||
VISION | ||||||||||||||
US | 899 | 710 | 26.6 | 26.6 | — | |||||||||
Intl | 1,389 | 1,143 | 21.5 | 16.3 | 5.2 | |||||||||
WW | 2,288 | 1,853 | 23.5 | 20.3 | 3.2 | |||||||||
CONTACT LENSES / OTHER | ||||||||||||||
US | 629 | 530 | 18.7 | 18.7 | — | |||||||||
Intl | 1,022 | 906 | 12.8 | 8.0 | 4.8 | |||||||||
WW | 1,651 | 1,436 | 15.0 | 12.0 | 3.0 | |||||||||
SURGICAL | ||||||||||||||
US | 270 | 180 | 50.0 | 50.0 | — | |||||||||
Intl | 367 | 237 | 54.9 | 48.3 | 6.6 | |||||||||
WW | 637 | 417 | 52.8 | 49.1 | 3.7 | |||||||||
TOTAL MEDICAL DEVICES | ||||||||||||||
US | 6,426 | 6,321 | 1.7 | 1.7 | — | |||||||||
Intl | 7,313 | 6,698 | 9.2 | 3.3 | 5.9 | |||||||||
WW | $ | 13,739 | 13,019 | 5.5 | % | 2.5 | % | 3.0 | % | |||||
*Percentage greater than 100% or not meaningful | ||||||||||||||
(1) Operational growth excludes the effect of translational currency | ||||||||||||||
(2) Unaudited | ||||||||||||||
(3) Reported as U.S. sales | ||||||||||||||
(4) Products acquired from Actelion acquisition on June 16, 2017 | ||||||||||||||
(5) Prior year amounts have been reclassified to conform to current year product disclosure |